Robert Dillman

Company: Aivita Biomedical

Job title: Chief Medical Officer

Seminars:

Using the Antigenic Signature of Self-renewing GBM Cells to Target Low & High Mutational Tumor Burden 9:45 am

Autologous dendritic cells loaded with autologous tumor antigens from self-renewing tumor initiating cells as personal therapeutic cancer vaccines Lessons learned from a single-arm phase 2 trial in primary GBM Randomized, blinded phase 3 trial in primary GBMRead more

day: Conference Day 2